Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes: Results of the Prospective Population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study
Overview
Authors
Affiliations
A subclinical inflammatory reaction has been shown to precede the onset of type 2 (non-insulin-dependent) diabetes. We therefore examined prospectively the effects of the central inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) on the development of type 2 diabetes. We designed a nested case-control study within the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study including 27,548 individuals. Case subjects were defined to be those who were free of type 2 diabetes at baseline and subsequently developed type 2 diabetes during a 2.3-year follow-up period. A total of 192 cases of incident type 2 diabetes were identified and matched with 384 non-disease-developing control subjects. IL-6 and TNF-alpha levels were found to be elevated in participants with incident type 2 diabetes, whereas IL-1beta plasma levels did not differ between the groups. Analysis of single cytokines revealed IL-6 as an independent predictor of type 2 diabetes after adjustment for age, sex, BMI, waist-to-hip ratio (WHR), sports, smoking status, educational attainment, alcohol consumption, and HbA(1c) (4th vs. the 1st quartile: odds ratio [OR] 2.6, 95% CI 1.2-5.5). The association between TNF-alpha and future type 2 diabetes was no longer significant after adjustment for BMI or WHR. Interestingly, combined analysis of the cytokines revealed a significant interaction between IL-1beta and IL-6. In the fully adjusted model, participants with detectable levels of IL-1beta and elevated levels of IL-6 had an independently increased risk to develop type 2 diabetes (3.3, 1.7-6.8), whereas individuals with increased concentrations of IL-6 but undetectable levels of IL-1beta had no significantly increased risk, both compared with the low-level reference group. These results were confirmed in an analysis including only individuals with HbA(1c) <5.8% at baseline. Our data suggest that the pattern of circulating inflammatory cytokines modifies the risk for type 2 diabetes. In particular, a combined elevation of IL-1beta and IL-6, rather than the isolated elevation of IL-6 alone, independently increases the risk of type 2 diabetes. These data strongly support the hypothesis that a subclinical inflammatory reaction has a role in the pathogenesis of type 2 diabetes.
Loglo A, Antwi P, Abass K, Osei-Mireku S, Amofa G, Ofori E PLoS Negl Trop Dis. 2025; 19(3):e0012871.
PMID: 40072975 PMC: 11902277. DOI: 10.1371/journal.pntd.0012871.
Dynamic roles of tumor-infiltrating B lymphocytes in cancer immunotherapy.
Song S, Wang C, Chen Y, Zhou X, Han Y, Zhang H Cancer Immunol Immunother. 2025; 74(3):92.
PMID: 39891668 PMC: 11787113. DOI: 10.1007/s00262-024-03936-7.
Anemia in diabetes mellitus: Pathogenetic aspects and the value of early erythropoietin therapy.
Antoniadou C, Gavriilidis E, Ritis K, Tsilingiris D Metabol Open. 2025; 25:100344.
PMID: 39886103 PMC: 11780985. DOI: 10.1016/j.metop.2024.100344.
Sun L, Yuan H, Ma H, Wang Y Metabolites. 2025; 15(1).
PMID: 39852351 PMC: 11768040. DOI: 10.3390/metabo15010008.
Zhou J, Yin S, Du L, Xue X, He Q, Zhao N Nutrients. 2025; 17(1.
PMID: 39796481 PMC: 11723060. DOI: 10.3390/nu17010047.